Over the past six months, Merck’s stock price fell to $80.05. Shareholders have lost 6.6% of their capital, which is ...

Merck (MRK) recently announced positive topline results from its Phase 3 KEYNOTE-905 trial, showcasing efficacy for KEYTRUDA in patients with muscle-invasive bladder cancer, which adds substantial ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Merck & Co., Inc. has kicked off two Phase 3 trials for its experimental PrEP therapy, MK-8527. **The trials, EXPrESSIVE-10 ...

Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...

Merck & Co., Inc. (NYSE:MRK) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Merck & Co., Inc. (NYSE:MRK) has ...

This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

US pharma giant Pfizer and Japan’s Astellas Pharma today announced positive top-line results from the Phase III EV-303 ...

THQ offers a high 14% yield and diversified healthcare exposure, but recent performance has lagged, with a 26.6% price drop ...

Major indices were in the green at the opening bell on Tuesday as traders digested last month's consumer price index.